{"id":22380,"date":"2023-04-20T18:11:56","date_gmt":"2023-04-20T12:41:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=22380"},"modified":"2023-04-20T18:33:27","modified_gmt":"2023-04-20T13:03:27","slug":"medtech-news-for-biomerieux-senseonics-rapidai-neuspera","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera","title":{"rendered":"Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma; Oxford Nanopore and bioM\u00e9rieux Signs Partnership Agreement; Boomerang Medical\u2019s Bioelectronic Device for Inflammatory Bowel Disease; Senseonics\u2019s ENHANCE Clinical Trial Updates; RapidAI\u2019s Non-Contrast CT Imaging Product; FDA Clearance for Neuspera Medical\u2019s Peripheral Nerve Stimulation System"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d299f4bd188\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d299f4bd188\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#Bausch_Lomb_and_Heidelberg_Engineering_Introduced_SeeLuma%E2%84%A2_Fully_Digital_Surgical_Visualization_Platform\" >Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma&#x2122; Fully Digital Surgical Visualization Platform&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#RapidAI_Received_First_and_Only_FDA_510k_Clearance_of_Non-Contrast_CT_Imaging_Product_to_Accelerate_Acute_Stroke_Triage\" >RapidAI Received First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#First_Patients_Enrolled_in_Boomerang_Medical_Multi-Center_Clinical_Trial_Evaluating_Breakthrough_Bioelectronic_Device_for_Inflammatory_Bowel_Disease\" >First Patients Enrolled in Boomerang Medical Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#Oxford_Nanopore_and_bioMerieux_Entered_into_a_Strategic_Partnership_Agreement_to_Develop_Innovative_Infectious_Disease_Diagnostics\" >Oxford Nanopore and bioM\u00e9rieux Entered into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#Neuspera_Medical_Announced_FDA_Clearance_of_Peripheral_Nerve_Stimulation_System\" >Neuspera Medical Announced FDA Clearance of Peripheral Nerve Stimulation System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\/#Senseonics_Announced_the_First_Pediatric_Study_Participant_Insertions_in_the_ENHANCE_Clinical_Trial\" >Senseonics Announced the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-bausch-lomb-and-heidelberg-engineering-introduced-seeluma-fully-digital-surgical-visualization-platform\"><span class=\"ez-toc-section\" id=\"Bausch_Lomb_and_Heidelberg_Engineering_Introduced_SeeLuma%E2%84%A2_Fully_Digital_Surgical_Visualization_Platform\"><\/span><strong>Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma&#x2122; Fully Digital Surgical Visualization Platform&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 13, 2023<\/strong>, Bausch + Lomb, a leading global eye health company dedicated to helping people see better and to live better, and Heidelberg Engineering, announced the introduction of the SeeLuma&#x2122; Fully Digital Surgical Visualization Platform.&nbsp;<\/p>\n\n\n\n<p>The SeeLuma&#x2122; Fully Digital Surgical Visualization Platform is meant to provide and facilitating ophthalmic surgeons with a new level of visualization compared to optical, hybrid, and retrofitted microscopes to perform even the most complex surgical procedures.&nbsp;<\/p>\n\n\n\n<p>The features such as a heads-up 3D monitor, multiple digital display options, and an intuitive interface present in SeeLuma offer excellent visualization, ergonomics, smooth workflow, and an immersive educational experience.&nbsp;<\/p>\n\n\n\n<p><strong>Premium Image Quality Enhances Visualization<\/strong><\/p>\n\n\n\n<p>SeeLuma allows surgeons to handle complicated surgical procedures in a comparatively easy manner by offering high-quality images relating to the depth of field, color reproduction, contrast, and resolution. With the use of next-generation 3D 55\u201d and 31\u201d 4K monitors, as well as unique digital binoculars, the platform facilitates 3D heads-up surgery. The embedded functions in SeeLuma assist users in better distinguishing anatomical features by allowing them to highlight and enhance anatomical landmarks.&nbsp;<\/p>\n\n\n\n<p><strong>Multiple Digital Display Options Support Ergonomic Positioning<\/strong><\/p>\n\n\n\n<p>The platform possesses multiple digital display options, enabling surgeons to operate ergonomically. They can view the 55\u201d or 31\u201d 3D 4K monitor straight ahead of them through a C-shaped suspension arm. The digital binoculars are mounted onto a separate suspension arm and allow surgeons to take on an ergonomic posture and work with ease.<\/p>\n\n\n\n<p><strong>Intuitive Interface Facilitates Efficient Workflow<\/strong><\/p>\n\n\n\n<p>SeeLuma offers a user-friendly UI with extensive settings. Nurses or the operating surgeon themselves can use the foot switch to directly control key system functionality from the on-screen menu. System variables like white balance, image inversion, zoom and focus speeds, and foot control layouts are automatically adjusted to surgical steps. Furthermore, the user interface offers simple, quick access to system capabilities in a manner akin to that of personal computers or cell phones.<\/p>\n\n\n\n<p><strong>Interactive Platform Provides Immersive Educational Experience<\/strong><\/p>\n\n\n\n<p>All parties involved in the process, both inside and outside the operating room (OR), can take part in it fully through the use of SeeLuma. The system enables trainees and stakeholders to observe and foresee surgical processes as they happen while in the OR and\/or at a remote location. Surgeons can concurrently connect numerous wireless displays. Also, the system can be useful to facilitate cooperation and learning during live surgery events. Surgeons can use the platform&#8217;s Assist Mode to send and receive real-time support through the touchscreen interface and make annotations or notes on the operative image.<\/p>\n\n\n\n<p>SeeLuma will be introduced in the United States and Western Europe this month, with additional countries to follow.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cAs part of our broader mission, Bausch + Lomb aims to provide ophthalmic surgeons around the world with innovative visualization and intraoperative diagnostic technologies that enhance the surgical experience to ultimately help deliver better patient outcomes. The launch of SeeLuma is an important milestone on this journey, as it will serve as one of the key foundations for our future image-guided surgical applications.\u201d<\/p>\n<cite><strong>Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cSeeLuma addresses several challenges that many surgeons often struggle with when using surgical microscopes that are currently available. Having access to a platform that offers cutting edge visualization, efficient workflow and ergonomics, and educational features has the potential to really change the landscape and ultimately deliver tremendous benefits for current and future generations of surgeons, as well as their practices and patients.\u201d<\/p>\n<cite><strong>Siegfried Priglinger, professor, director, and chairman of, the University Eye Hospital of the Ludwig-Maximilians-Universit\u00e4t, Munich, Germany<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ophthalmic-surgical-devices-market\"><strong>Ophthalmic Surgical Devices<\/strong><strong> <\/strong><strong>Market<\/strong><\/a>\u201d report, the global ophthalmic surgical devices market was valued at <strong>USD 8.91 billion<\/strong> in 2021 and will grow at a <strong>CAGR<\/strong> of <strong>5.09%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 11.97 billion<\/strong> by 2027. The ophthalmic surgical devices market is observing remarkable market growth due to the factors such as the growing prevalence of various ophthalmic disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/glaucoma-market\"><strong>glaucoma<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/cataract-market\"><strong>cataract<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/refractive-errors-epidemiology-forecast\"><strong>refractive errors<\/strong><\/a>, and others.&nbsp;<\/p>\n\n\n\n<p>Moreover, the rising burden of the geriatric population, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-epidemiology-forecast\"><strong>rising prevalence of diabetes<\/strong><\/a>, and other risk factors for ophthalmic disorders will aid in driving the market for ophthalmic surgical devices. Additionally, the rising awareness about vision impairment, surging technological advancements in the devices, the increasing product launches and approvals, the presence of key players in the market, and other factors will create a requisite for <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-drainage-devices-market\"><strong>ophthalmic surgical devices<\/strong><\/a> in the market. Therefore, the market for ophthalmic surgical devices is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rapidai-received-first-and-only-fda-510-k-clearance-of-non-contrast-ct-imaging-product-to-accelerate-acute-stroke-triage\"><span class=\"ez-toc-section\" id=\"RapidAI_Received_First_and_Only_FDA_510k_Clearance_of_Non-Contrast_CT_Imaging_Product_to_Accelerate_Acute_Stroke_Triage\"><\/span><strong>RapidAI Received First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 18, 2023<\/strong>, RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow received 510(k) clearance by the US Food and Drug Administration for its Rapid NCCT Stroke, becoming the first and only FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from value-based CT imaging.<\/p>\n\n\n\n<p>Based on artificial intelligence (AI) technology, Rapid NCCT Stroke is used to analyze non-contrast CT (NCCT) images to determine suspicion of ICH and LVO of the distal internal carotid artery (ICA) and middle cerebral artery (MCA-M1). The fully automated system then delivers triage and prioritization notifications through PACS, email, and the Rapid mobile app.&nbsp;<\/p>\n\n\n\n<p>Rapid NCCT Stroke is a major addition to the RapidAI suite of non-contrast-based solutions for stroke and trauma care allowing hospitals and care teams to make time-sensitive workflow and transfer decisions faster.<\/p>\n\n\n\n<p>Rapid NCCT Stroke assist teams in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Shortening the time from the door to imaging and the door to the choice<\/li>\n\n\n\n<li>Making faster transfer decisions<\/li>\n\n\n\n<li>Improving access to modern, value-based CT imaging technologies, which may enhance decision-making and may have an influence on patient outcomes<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThis technology will not only have an enormous impact on stroke care here in the U.S. but also globally by giving care teams at small, local, or regional facilities around the world access to advanced clinical decision support technology too often only available at comprehensive stroke centers. Our hope is that by providing better information early for more informed treatment and transfer decisions, Rapid NCCT Stroke will support faster stroke care and better patient outcomes. This is an incredible achievement for the team and yet another example of RapidAI\u2019s continued leadership in creating the next evolution of stroke care technology.\u201d<\/p>\n<cite><strong>Karim Karti, CEO of RapidAI<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/intracranial-hemorrhage-devices-market\"><strong>Intracranial Hemorrhage (ICH) Devices Market<\/strong><\/a>\u201d report, the global intracranial hemorrhage (ICH) Devices Market was valued at <strong>USD 1.59 billion<\/strong> in 2021, growing at a <strong>CAGR<\/strong> of <strong>6.65%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 2.35 billion<\/strong> by 2027. The increase in demand for intracranial hemorrhage (ICH) devices is primarily attributed to the rising cases of brain disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/ischemic-stroke-epidemiology-forecast\"><strong>stroke<\/strong><\/a>, cerebral\/brain aneurysm, and others. Further, the growing burden of the old age population suffering from brain disorders, and shifting focus towards the development of technologically advanced ICH devices, among others, are thereby contributing to the growth of the intracranial hemorrhage (ICH) devices market during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-patients-enrolled-in-boomerang-medical-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\"><span class=\"ez-toc-section\" id=\"First_Patients_Enrolled_in_Boomerang_Medical_Multi-Center_Clinical_Trial_Evaluating_Breakthrough_Bioelectronic_Device_for_Inflammatory_Bowel_Disease\"><\/span><strong>First Patients Enrolled in Boomerang Medical Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 17, 2023, <\/strong>Boomerang Medical, a women-led bioelectronic medicine company announced that the first patients were enrolled in the clinical trial meant for evaluating the application of nerve stimulation as a potential treatment for Crohn\u2019s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease (IBD) in the United States.&nbsp;<\/p>\n\n\n\n<p>The trial will examine the safety and performance of the bioelectronic device which already received the breakthrough device designation from the US FDA earlier this year. The device will be used in patients with mild to moderately severe Crohn\u2019s disease and ulcerative colitis, regardless of whether they have previously undergone advanced therapy such as biologics.<\/p>\n\n\n\n<p>The first patient was enrolled in the study in Kansas, followed by Columbia University Irving Medical Center in New York, NY.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cCrohn\u2019s disease and ulcerative colitis remain very difficult to manage, despite the numerous approved biologic therapies available. The Boomerang clinical trial aims to investigate a novel alternative intervention \u2013 a device to treat IBD. We are excited to be investigating this promising new treatment.\u201d<\/p>\n<cite><strong>Michael Lievens, M.D., principal investigator for the Boomerang trial at Kansas Gastroenterology, LLC. Michael<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;The most fascinating aspect of this study is the possibility of managing IBD simply by stimulating the patient\u2019s autonomic system to release anti-inflammatory mediators.\u201d\u00a0<\/p>\n<cite><strong>Marco Zoccali, M.D., FACS, principal investigator for the Boomerang trial at Columbia University Irving Medical Center<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are thrilled to enroll the first patients in this clinical trial of our breakthrough bioelectronic device for IBD. This trial represents a major milestone in our efforts to develop a new therapeutic approach for patients suffering from Crohn&#8217;s disease and ulcerative colitis. We are grateful for the support of our clinical trial partners and the FDA, and we look forward to advancing this important work.\u201d<\/p>\n<cite><strong>Heather Simonsen, CEO of Boomerang Medical<\/strong><\/cite><\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-bowel-disease-medtech-market\"><strong>Inflammatory Bowel Disease Market<\/strong><\/a><strong>\u201d <\/strong>report, the global inflammatory bowel disease (IBD) market is estimated to grow at a <strong>CAGR<\/strong> of <strong>5.72%<\/strong> during the forecast period from 2022 to 2027. The IBD market is slated to witness prosperity owing to factors such as the rising prevalence of IBD, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-epidemiology-forecast\"><strong>Crohn&#8217;s Disease (CD)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-epidemiology-forecast\"><strong>Ulcerative Colitis (UC)<\/strong><\/a>, increasing risk factors for IBD, an increasing number of clinical trials for IBD drugs, and the growing focus on improving the safety and usability of IBD drugs and diagnostic devices are further expected to result in the appreciable revenue growth in the IBD market during the forecast period (2022-2027).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-oxford-nanopore-and-biomerieux-entered-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\"><span class=\"ez-toc-section\" id=\"Oxford_Nanopore_and_bioMerieux_Entered_into_a_Strategic_Partnership_Agreement_to_Develop_Innovative_Infectious_Disease_Diagnostics\"><\/span><strong>Oxford Nanopore and bioM\u00e9rieux Entered into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 14, 2023, <\/strong>Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore-based molecular sensing technology, and bioM\u00e9rieux SA, a world leader in the field of <a href=\"https:\/\/www.delveinsight.com\/report-store\/in-vitro-diagnostics-market\"><strong>in vitro diagnostics<\/strong><\/a>, announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.<strong>&nbsp;<\/strong><\/p>\n\n\n\n<p>Nanopore-based sequencing which allows analysis of long DNA or RNA fragments is a novel technology that works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. Thus, to provide the specific DNA or RNA sequence, the resulting signal is decoded.&nbsp;<\/p>\n\n\n\n<p>This technology is ideal for the rapid and cost-effective characterization of microbial pathogens in clinical samples owing to its unique real-time and scalable features.&nbsp;<\/p>\n\n\n\n<p>Oxford Nanopore is uniquely positioned to provide nanopore-based sequencing solutions that provide comprehensive results and shorten the time to results for infectious diseases research and diagnostic applications by offering quick and accurate identification of microbial pathogens and associated <a href=\"https:\/\/www.delveinsight.com\/report-store\/antimicrobial-resistance-amr-epidemiology-forecast\"><strong>antimicrobial resistance<\/strong><\/a>.<\/p>\n\n\n\n<p>An assay to identify pathogens in typically sterile clinical samples, a test to determine antibiotic resistance for tuberculosis, and validating Oxford Nanopore&#8217;s sequencing platform with BIOM\u00c9RIEUX EPISEQ\u00ae CS application for quick infection outbreak monitoring in patient-care settings are the initial areas of collaboration.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are pleased to partner with bioM\u00e9rieux\u2019s IVD expertise to add powerful new tools for the fight against infectious disease. By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key.\u201d\u00a0<\/p>\n<cite><strong>Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are excited to enter into a research partnership with Oxford Nanopore in the field of infectious diseases. New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction.&#8221;<\/p>\n<cite><strong>Alexandre M\u00e9rieux, bioM\u00e9rieux Chairman and CEO<\/strong><\/cite><\/blockquote>\n\n\n\n<p><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/infectious-disease-diagnostics-market\" class=\"ek-link\"><strong>Infectious Disease <\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/infectious-disease-diagnostics-market\" class=\"ek-link\">Diagnostics <\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/infectious-disease-diagnostics-market\" class=\"ek-link\"><strong>Market<\/strong><\/a>\u201d report, the global infectious disease diagnostics market was valued at <strong>USD 38.52 billion<\/strong> in 2021 and is estimated to grow at a <strong>CAGR<\/strong> of <strong>3.80%<\/strong> during the forecast period (2022\u20132027) to reach <strong>USD 48.10 billion<\/strong> by 2027. The infectious disease market is slated to witness prosperity owing to factors such as the growing prevalence of infectious diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-competitive-landscape\"><strong>COVID-19<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight\"><strong>malaria<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/typhoid-fever-market\"><strong>typhoid<\/strong><\/a>, and others, rising incidences of epidemics and pandemics, and the growing focus on improving the safety, affordability, and usability of infectious disease diagnostics for end-users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2022-2027).\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuspera-medical-announced-fda-clearance-of-peripheral-nerve-stimulation-system\"><span class=\"ez-toc-section\" id=\"Neuspera_Medical_Announced_FDA_Clearance_of_Peripheral_Nerve_Stimulation_System\"><\/span><strong>Neuspera Medical Announced FDA Clearance of Peripheral Nerve Stimulation System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>April 18, 2023<\/strong>, Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, received the US Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system.&nbsp;<\/p>\n\n\n\n<p>Peripheral nerve stimulation (PNS) is delivered through the Neuspera system using a wireless, less intrusive, and more flexible platform than commercially available technologies. It is the first PNS device to provide an ultra-miniaturized alternative, which could improve patient comfort and procedural flexibility.<\/p>\n\n\n\n<p>Along with being 75x smaller than the smallest commercial implantable pulse generator, the Neuspera system provides physicians the opportunity for deeper anatomical targets compared to current technologies available today.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;We look forward to bringing this innovative technology to physicians and patients in the US. The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients&#8217; health and quality of life.&#8221;\u00a0<\/p>\n<cite><strong>Steffen Hovard, CEO of Neuspera Medical. <\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-nerve-stimulators-market\"><strong>Peripheral Nerve Stimulators Market<\/strong><\/a>\u201d report, the global peripheral nerve stimulators market is growing at a <strong>CAGR <\/strong>of <strong>6.9%<\/strong> during the forecast period from 2022 to 2027. The increase in demand for peripheral nerve stimulators (PNS) is primarily attributed to the increase in the number of patients suffering from nerve injuries, effective technologies in PNS, growing awareness of peripheral nerve stimulators among people, growing <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-market-insight\"><strong>demand for chronic pain management therapies<\/strong><\/a>, increasing prevalence of diseases which can drive pain, increasing geriatric population, <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><strong>rising of obese population<\/strong><\/a>, among others are anticipated to bolster the market growth, thereby contributing to the growth of the peripheral nerve stimulators market during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-senseonics-announced-the-first-pediatric-study-participant-insertions-in-the-enhance-clinical-trial\"><span class=\"ez-toc-section\" id=\"Senseonics_Announced_the_First_Pediatric_Study_Participant_Insertions_in_the_ENHANCE_Clinical_Trial\"><\/span><strong>Senseonics Announced the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>April 18, 2023,<\/strong> Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-epidemiology-forecast\"><strong>people with diabetes<\/strong><\/a>, announced the insertion of the first pediatric study participant with Eversense\u00ae 365-day system in the ENHANCE clinical trial which is designed to evaluate the accuracy and safety of the Eversense system for up to one year.<\/p>\n\n\n\n<p>The trial is being held at the AMCR Institute, a clinical research center focused on <a href=\"https:\/\/www.delveinsight.com\/report-store\/prediabetes-market\"><strong>pre-diabetes<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market\"><strong>Type 1 Diabetes<\/strong><\/a><strong>,<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\"><strong>type 2 diabetes<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><strong>obesity<\/strong><\/a>, under the direction of Dr. Timothy Bailey.&nbsp;<\/p>\n\n\n\n<p>In four facilities across the United States, Eversense systems were implanted in more than 165 adult participants. The last patient is anticipated to complete their 365-day visit during the third quarter of 2023, and enrollment for the 365-day sensor configuration was finished in September 2022.&nbsp;<\/p>\n\n\n\n<p>The trial&#8217;s data will also be used to support an application for integrated continuous glucose monitoring, or iCGM, designation in 2023. The first pediatric research participants were enrolled in Q2 2023 after an investigational device exemption (IDE) supplement was submitted and approved for the trial&#8217;s expansion to include pediatric patients between the ages of 14 and 18.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cIt is a priority for Senseonics to extend the benefits of Eversense to the pediatric patient population. Positive results in the trial would support expanding our ability to transform lives in the global diabetes community. The differentiated features of our long-term implantable Eversense system are uniquely suited to benefit pediatrics and enable parents and their children to work together to manage diabetes. Young people would have the ability to remove their transmitters to participate in activities, without having to worry about wasting valuable sensors, and enjoy ring-free vibrating alarms to help manage their sugar levels without attracting unwanted attention to themselves.\u201d\u00a0<\/p>\n<cite><strong>Francine Kaufman, M.D., Chief Medical Officer of Senseonics<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;I am excited to be one of the investigators in the ENHANCE Trial and thrilled to be the first to enroll subjects in the pediatric extension.\u201d Bailey added, \u201cIn our experience, CGM is an essential tool for all people with diabetes, especially for those who take insulin. We believe having additional accurate, and especially long-term wear, CGM options for our pediatric patients and their families will increase utilization of the technology and improve the quality of their lives.\u201d<\/p>\n<cite><strong>Timothy Bailey, M.D., head of AMCR Institute in Escondido, California<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\"><strong>Blood Glucose Monitoring Systems Market<\/strong><\/a>\u201d report, the global blood glucose monitoring systems market was valued at <strong>USD 13.06 billion<\/strong> in 2021, growing at a <strong>CAGR<\/strong> of <strong>7.72%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 20.40 billion<\/strong> by 2027. <\/p>\n\n\n\n<p>The escalating demand for blood glucose monitoring systems is predominantly attributed to the increasing prevalence of diabetes among the population across the globe and the growing burden of the geriatric population who are susceptible to <a href=\"https:\/\/www.delveinsight.com\/report-store\/hyperglycemia-market\"><strong>developing hyperglycemia<\/strong><\/a>. In addition, the spike in technologically advanced blood glucose monitoring device product launches and government initiatives to raise awareness regarding proper diabetes management, among others are the factors likely to spur the global blood glucose monitoring systems market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma&#x2122; Fully Digital Surgical Visualization Platform&nbsp; On April 13, 2023, Bausch + Lomb, a leading global eye health company dedicated to helping people see better and to live better, and Heidelberg Engineering, announced the introduction of the SeeLuma&#x2122; Fully Digital Surgical Visualization Platform.&nbsp; The SeeLuma&#x2122; Fully Digital Surgical [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":22382,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":10,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20603,20601,19738,20428,20607,20606,20605,20604,2753,17020,17021,16779,16975,18799,20117,20116,2006,19279,19277,20602,18746],"industry":[17226],"therapeutic_areas":[17242,17240,17245,17244],"class_list":["post-22380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-stroke","tag-bausch-lomb","tag-blood-glucose-monitoring-systems-market","tag-boomerang-medical","tag-infectious-disease-diagnostics","tag-intracranial-hemorrhage","tag-intracranial-hemorrhage-ich-devices","tag-intracranial-hemorrhage-ich-devices-market","tag-medical-device","tag-medical-devices","tag-medical-devices-market","tag-medtech","tag-medtech-market","tag-medtech-news","tag-ophthalmic-surgical-devices","tag-ophthalmic-surgical-devices-market","tag-oxford-nanopore","tag-peripheral-nerve-stimulators","tag-peripheral-nerve-stimulators-market","tag-rapidai","tag-senseonics","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | bioM\u00e9rieux, Senseonics, RapidAI, Neuspera<\/title>\n<meta name=\"description\" content=\"Bausch + Lomb&#039;s SeeLuma; bioM\u00e9rieux-Oxford Nanopore&#039;s Agreement; Boomerang&#039;s Bioelectronic Device; Neuspera Medical\u2019s PNS System; Senseonics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | bioM\u00e9rieux, Senseonics, RapidAI, Neuspera\" \/>\n<meta property=\"og:description\" content=\"Bausch + Lomb&#039;s SeeLuma; bioM\u00e9rieux-Oxford Nanopore&#039;s Agreement; Boomerang&#039;s Bioelectronic Device; Neuspera Medical\u2019s PNS System; Senseonics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T12:41:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-20T13:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | bioM\u00e9rieux, Senseonics, RapidAI, Neuspera","description":"Bausch + Lomb's SeeLuma; bioM\u00e9rieux-Oxford Nanopore's Agreement; Boomerang's Bioelectronic Device; Neuspera Medical\u2019s PNS System; Senseonics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera","og_locale":"en_US","og_type":"article","og_title":"MedTech News | bioM\u00e9rieux, Senseonics, RapidAI, Neuspera","og_description":"Bausch + Lomb's SeeLuma; bioM\u00e9rieux-Oxford Nanopore's Agreement; Boomerang's Bioelectronic Device; Neuspera Medical\u2019s PNS System; Senseonics","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-04-20T12:41:56+00:00","article_modified_time":"2023-04-20T13:03:27+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera","name":"MedTech News | bioM\u00e9rieux, Senseonics, RapidAI, Neuspera","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical.png","datePublished":"2023-04-20T12:41:56+00:00","dateModified":"2023-04-20T13:03:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Bausch + Lomb's SeeLuma; bioM\u00e9rieux-Oxford Nanopore's Agreement; Boomerang's Bioelectronic Device; Neuspera Medical\u2019s PNS System; Senseonics","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biomerieux-senseonics-rapidai-neuspera#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical.png","width":772,"height":482,"caption":"MedTech News for Bausch + Lomb, Heidelberg Engineering, Oxford Nanopore, bioM\u00e9rieux, Senseonics, Boomerang Medical, RapidAI, Neuspera Medical"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20181004\/MedTech-News-for-Bausch-Lomb-Heidelberg-Engineering-Oxford-Nanopore-bioMerieux-Senseonics-Boomerang-Medical-RapidAI-Neuspera-Medical-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Stroke<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bausch Lomb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blood Glucose Monitoring Systems Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Boomerang Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infectious Disease Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Intracranial Hemorrhage<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Intracranial Hemorrhage (ICH) Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Intracranial Hemorrhage (ICH) Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Surgical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Surgical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oxford Nanopore<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Nerve Stimulators<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Nerve Stimulators Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RapidAI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Senseonics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Stroke<\/span>","<span class=\"advgb-post-tax-term\">Bausch Lomb<\/span>","<span class=\"advgb-post-tax-term\">Blood Glucose Monitoring Systems Market<\/span>","<span class=\"advgb-post-tax-term\">Boomerang Medical<\/span>","<span class=\"advgb-post-tax-term\">Infectious Disease Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Intracranial Hemorrhage<\/span>","<span class=\"advgb-post-tax-term\">Intracranial Hemorrhage (ICH) Devices<\/span>","<span class=\"advgb-post-tax-term\">Intracranial Hemorrhage (ICH) Devices Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Surgical Devices<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Surgical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Oxford Nanopore<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Nerve Stimulators<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Nerve Stimulators Market<\/span>","<span class=\"advgb-post-tax-term\">RapidAI<\/span>","<span class=\"advgb-post-tax-term\">Senseonics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 20, 2023","modified":"Updated on Apr 20, 2023"},"absolute_dates_time":{"created":"Posted on Apr 20, 2023 6:11 pm","modified":"Updated on Apr 20, 2023 6:33 pm"},"featured_img_caption":"MedTech News for Bausch + Lomb, Heidelberg Engineering, Oxford Nanopore, bioM\u00e9rieux, Senseonics, Boomerang Medical, RapidAI, Neuspera Medical\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=22380"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/22382"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=22380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=22380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=22380"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=22380"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=22380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}